Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses

By Judge Heather M.   Buckland Robert J.   Holgate Carol E.   Storey Robert F.  

Platelets, Vol. 16, Iss. 7, 2005-11 ,pp. : 398-407

Informa Healthcare

Access to resources Recommend Favorite

Effects of P2Y₁ and P2Y₁₂ receptor antagonists on platelet aggregation induced by different agonists in human whole blood

By Storey Robert F.   Newby Linda J.   Heptinstall Stan  

Platelets, Vol. 12, Iss. 7, 2001-11 ,pp. : 443-447

Informa Healthcare

Access to resources Recommend Favorite

P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP

By Iyú David   Glenn Jackie R.   White Ann E.   Fox Sue C.   Dovlatova Natalia   Heptinstall Stan  

Platelets, Vol. 22, Iss. 7, 2011-11 ,pp. : 504-515

Informa Healthcare

Access to resources Recommend Favorite

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses

By Judge Heather   Buckland Robert   Sugidachi Atsuhiro   Jakubowski Joseph   Storey Robert  

Platelets, Vol. 19, Iss. 2, 2008-03 ,pp. : 125-133

Informa Healthcare

Access to resources Recommend Favorite

P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 6, Iss. 3, 2011-09 ,pp. : 207-214

Bentham Science Publishers

Access to resources Recommend Favorite